Literature DB >> 30104634

The immunoproteasome and thymoproteasome: functions, evolution and human disease.

Shigeo Murata1, Yousuke Takahama2,3, Masanori Kasahara4, Keiji Tanaka5.   

Abstract

The basic principle of adaptive immunity is to strictly discriminate between self and non-self, and a central challenge to overcome is the enormous variety of pathogens that might be encountered. In cell-mediated immunity, immunological discernment takes place at a molecular or cellular level. Central to both mechanisms of discernment is the generation of antigenic peptides associated with MHC class I molecules, which is achieved by a proteolytic complex called the proteasome. To adequately accomplish the discrimination between self and non-self that is essential for adaptive immunity and self-tolerance, two proteasome subtypes have evolved via gene duplication: the immunoproteasome and the thymoproteasome. In this Review, we describe various aspects of these immunity-dedicated proteasomes, from their discovery to recent findings.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30104634     DOI: 10.1038/s41590-018-0186-z

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  86 in total

Review 1.  Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases.

Authors:  Ivona Aksentijevich; Oskar Schnappauf
Journal:  Nat Rev Rheumatol       Date:  2021-05-25       Impact factor: 20.543

Review 2.  Thymoproteasome and peptidic self.

Authors:  Yousuke Takahama; Izumi Ohigashi; Shigeo Murata; Keiji Tanaka
Journal:  Immunogenetics       Date:  2018-10-15       Impact factor: 2.846

Review 3.  Thymus machinery for T-cell selection.

Authors:  Kenta Kondo; Izumi Ohigashi; Yousuke Takahama
Journal:  Int Immunol       Date:  2019-03-05       Impact factor: 4.823

Review 4.  Origin and evolution of the specialized forms of proteasomes involved in antigen presentation.

Authors:  Masanori Kasahara; Martin F Flajnik
Journal:  Immunogenetics       Date:  2019-01-24       Impact factor: 2.846

5.  Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo.

Authors:  Marquicia R Pierce; Reeder M Robinson; Tannya R Ibarra-Rivera; Michael C Pirrung; Nathan G Dolloff; André S Bachmann
Journal:  Leuk Res       Date:  2019-11-12       Impact factor: 3.156

6.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.

Authors:  Wenhu Zhan; Hao-Chi Hsu; Trevor Morgan; Tierra Ouellette; Kristin Burns-Huang; Ryoma Hara; Adrian G Wright; Toshihiro Imaeda; Rei Okamoto; Kenjiro Sato; Mayako Michino; Manoj Ramjee; Kazuyoshi Aso; Peter T Meinke; Michael Foley; Carl F Nathan; Huilin Li; Gang Lin
Journal:  J Med Chem       Date:  2019-10-15       Impact factor: 7.446

7.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

8.  PITHD1 is a proteasome-interacting protein essential for male fertilization.

Authors:  Hiroyuki Kondo; Takafumi Matsumura; Mari Kaneko; Kenichi Inoue; Hidetaka Kosako; Masahito Ikawa; Yousuke Takahama; Izumi Ohigashi
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

9.  Proteasome regulation by reversible tyrosine phosphorylation at the membrane.

Authors:  Lu Chen; Yanan Zhang; Xin Shu; Qiong Chen; Tiantian Wei; Heman Wang; Xiaorong Wang; Qirou Wu; Xiaomei Zhang; Xiaoyan Liu; Suya Zheng; Lan Huang; Junyu Xiao; Chao Jiang; Bing Yang; Zhiping Wang; Xing Guo
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

10.  Down-regulation of the islet-specific zinc transporter-8 (ZnT8) protects human insulinoma cells against inflammatory stress.

Authors:  Chengfeng Merriman; Dax Fu
Journal:  J Biol Chem       Date:  2019-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.